RecruitingPhase 3NCT06563895
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Sponsor: Eidos Therapeutics, a BridgeBio company
New Brunswick, NJ · +39 more sites